Topical statins in the treatment of porokeratosis: a systematic review

Clinical Snapshot

Key Findings

• P Value: Not applicable (descriptive analysis)

• Effect Size: 92% response rate (87 of 95 patients)

• Primary Outcome: Clinical improvement (partial resolution or lesion size reduction)

• Nnt Or Sensitivity: NNT approximately 1.1 (assuming baseline improvement rate near zero)

• Confidence Interval: Not reported

Clinical Application

Limited by requirement for compounded formulations; variable quality control and standardization issues Off-label prescribing permitted under TGA regulations; compounding pharmacy access required; no PBS listing for this indication; RACGP guidelines do not currently address topical statins for dermatological conditions Patients with porokeratosis seeking alternative therapy options, particularly those with treatment-resistant disease

Abstract

Porokeratosis is a chronic disorder of keratinization associated with significant morbidity and no spontaneous resolution. Currently, there are no therapies approved by the US Food and Drug Administration (FDA). However, the off-label use of topical statins - targeting the mevalonate pathway - has shown promise as a novel therapeutic strategy. This systematic review aims to evaluate the efficacy and safety of topical statins in the treatment of porokeratosis. We conducted a systematic review of the PubMed, Semantic Scholar and Cochrane databases from 1 January 2015 to 15 February 2025, identifying clinical studies evaluating topical statin therapy (atorvastatin, fluvastatin, lovastatin, rosuvastatin or simvastatin) in patients with any subtype of porokeratosis. Twenty-four studies encompassing 95 patients met the inclusion criteria. Most publications (88%) were case reports. The majority of patients (79%) received compounded topical lovastatin 2% or simvastatin 2%, typically in combination with cholesterol 2%. Clinical improvement - defined as partial resolution of symptoms or reduction in lesion size - was observed in 92% of patients (87 of 95), with onset of response reported as early as 4 weeks. Adverse events were reported in 15% of patients, primarily mild, localized dermatological reactions. Two patients discontinued treatment due to side effects. Topical statins appear to provide preliminary evidence of some clinical benefits in porokeratosis by inhibiting the mevalonate pathway, supporting a promising and plausible mechanism-based approach. However, the use of off-label compounded formulations introduces variability in efficacy and safety due to lack of quality control. The absence of FDA-approved therapies for porokeratosis represents an ongoing unmet therapeutic need warranting further investigation in prospective, controlled studies. Together, these preliminary case reports indicating clinical benefit encourage the development of an FDA-approved, Good Manufacturing Practice-quality topical statin formulation that is carefully evaluated in rigorous, well-designed clinical trials that demonstrate safety and substantial evidence of effectiveness.

References

1. 1.Martini, J., Buethe, M. G., & Atzmony, L. (2026). Topical statins in the treatment of porokeratosis: a systematic review. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag038